These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37561012)

  • 1. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.
    Park J; Ntelis S; Yunasan E; Downton KD; Yip TC; Munir KM; Haq N
    J Clin Endocrinol Metab; 2023 Dec; 109(1):279-292. PubMed ID: 37561012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
    Harris KB; Boland CL
    Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 Agonists in Type 1 Diabetes Mellitus.
    Janzen KM; Steuber TD; Nisly SA
    Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide analogues for type 2 diabetes mellitus.
    Shyangdan DS; Royle P; Clar C; Sharma P; Waugh N; Snaith A
    Cochrane Database Syst Rev; 2011 Oct; 2011(10):CD006423. PubMed ID: 21975753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.
    van Velsen EF; Lamers J; Blok V; van Leendert RJ; Kiewiet-Kemper RM
    Neth J Med; 2014 Dec; 72(10):523-7. PubMed ID: 26219757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
    JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
    Monami M; Dicembrini I; Nreu B; Andreozzi F; Sesti G; Mannucci E
    Acta Diabetol; 2017 Dec; 54(12):1101-1114. PubMed ID: 28932989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
    Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
    Tzefos M; Olin JL
    Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.